VEA
DSGN icon

Virtus ETF Advisers’s Design Therapeutics DSGN Stock Holding History

Virtus ETF Advisers’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,313
Closed -$43.2K – 438
2023
Q3 		$43.2K Sell
18,313
-1,824
-9% -$8.51K 0.03% 418
2023
Q2 		$127K Buy
20,137
+8,741
+77% +$53.5K 0.08% 325
2023
Q1 		$65.8K Sell
11,396
-4,378
-28% -$32.7K 0.04% 411
2022
Q4 		$162K Buy
15,774
+7,999
+103% +$108K 0.08% 330
2022
Q3 		$130K Buy
7,775
+59
+0.8% +$1.17K 0.05% 377
2022
Q2 		$108K Buy
+7,716
New +$104K 0.04% 414

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Virtus ETF Advisers's DSGN Position: Q4 2023 in Review

Virtus ETF Advisers sold out of Design Therapeutics (DSGN) in Q4 2023, closing a stake of 18,313 shares — an estimated $43.2K sold.

Virtus ETF Advisers first reported a position in DSGN in Q2 2022 and held it in 6 quarters. The position peaked at $162K in Q4 2022. 88 funds tracked by Wall St. Rank hold DSGN as of Q4 2023.

  • Virtus ETF Advisers reported no remaining Design Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Virtus ETF Advisers sold 18,313 Design Therapeutics shares in Q4 2023, an estimated $43.2K.
  • Virtus ETF Advisers first reported a position in Design Therapeutics in Q2 2022 and held it in 6 quarters.
  • Virtus ETF Advisers's Design Therapeutics position peaked at $162K in Q4 2022.
  • 88 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2023.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.